Tags

Type your tag names separated by a space and hit enter

Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.
Arterioscler Thromb Vasc Biol. 2006 May; 26(5):1101-6.AT

Abstract

OBJECTIVE

To examine the impact of ezetimibe, a selective inhibitor of intestinal cholesterol absorption, on the in vivo kinetics of apolipoproteins (apo) B-48 and B-100 in humans.

METHODS AND RESULTS

Kinetics of triglyceride-rich lipoprotein (TRL) apoB-48 and very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL) apoB-100 labeled with a stable isotope were assessed at baseline and at the end of 8 weeks of treatment with 10 mg/d of ezetimibe in 8 men with moderate primary hypercholesterolemia. Data were fit to a multicompartmental model using SAAMII to calculate fractional catabolic rate (FCR) and production rate (PR). Ezetimibe significantly decreased total and LDL cholesterol concentrations by -14.5% and -22.0% (P=0.004), respectively, with no significant change in plasma triglyceride and high-density lipoprotein (HDL) cholesterol levels. Ezetimibe had no significant effect on TRL apoB-48 kinetics and pool size (PS). However, VLDL and IDL apoB-100 FCRs were significantly increased (+31.2%, P=0.02 and +20.8%, P=0.04, respectively) with a concomitant elevation of VLDL apoB-100 PR (+20.9%, P=0.04). Furthermore, LDL apoB-100 PS was significantly reduced by -23.2% (P=0.004), caused by a significant increase in FCR of this lipoprotein fraction (+24.0%, P=0.04).

CONCLUSIONS

These results indicate that reduction of plasma LDL cholesterol concentration after treatment with ezetimibe is associated with an increase in FCR of apoB-100-containing lipoproteins.

Authors+Show Affiliations

Lipid Research Center, CHUL Research Center, Québec, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16528005

Citation

Tremblay, André J., et al. "Effect of Ezetimibe On the in Vivo Kinetics of apoB-48 and apoB-100 in Men With Primary Hypercholesterolemia." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 26, no. 5, 2006, pp. 1101-6.
Tremblay AJ, Lamarche B, Cohn JS, et al. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26(5):1101-6.
Tremblay, A. J., Lamarche, B., Cohn, J. S., Hogue, J. C., & Couture, P. (2006). Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(5), 1101-6.
Tremblay AJ, et al. Effect of Ezetimibe On the in Vivo Kinetics of apoB-48 and apoB-100 in Men With Primary Hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2006;26(5):1101-6. PubMed PMID: 16528005.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. AU - Tremblay,André J, AU - Lamarche,Benoît, AU - Cohn,Jeffrey S, AU - Hogue,Jean-Charles, AU - Couture,Patrick, Y1 - 2006/03/09/ PY - 2006/3/11/pubmed PY - 2006/5/13/medline PY - 2006/3/11/entrez SP - 1101 EP - 6 JF - Arteriosclerosis, thrombosis, and vascular biology JO - Arterioscler Thromb Vasc Biol VL - 26 IS - 5 N2 - OBJECTIVE: To examine the impact of ezetimibe, a selective inhibitor of intestinal cholesterol absorption, on the in vivo kinetics of apolipoproteins (apo) B-48 and B-100 in humans. METHODS AND RESULTS: Kinetics of triglyceride-rich lipoprotein (TRL) apoB-48 and very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and low-density lipoprotein (LDL) apoB-100 labeled with a stable isotope were assessed at baseline and at the end of 8 weeks of treatment with 10 mg/d of ezetimibe in 8 men with moderate primary hypercholesterolemia. Data were fit to a multicompartmental model using SAAMII to calculate fractional catabolic rate (FCR) and production rate (PR). Ezetimibe significantly decreased total and LDL cholesterol concentrations by -14.5% and -22.0% (P=0.004), respectively, with no significant change in plasma triglyceride and high-density lipoprotein (HDL) cholesterol levels. Ezetimibe had no significant effect on TRL apoB-48 kinetics and pool size (PS). However, VLDL and IDL apoB-100 FCRs were significantly increased (+31.2%, P=0.02 and +20.8%, P=0.04, respectively) with a concomitant elevation of VLDL apoB-100 PR (+20.9%, P=0.04). Furthermore, LDL apoB-100 PS was significantly reduced by -23.2% (P=0.004), caused by a significant increase in FCR of this lipoprotein fraction (+24.0%, P=0.04). CONCLUSIONS: These results indicate that reduction of plasma LDL cholesterol concentration after treatment with ezetimibe is associated with an increase in FCR of apoB-100-containing lipoproteins. SN - 1524-4636 UR - https://www.unboundmedicine.com/medline/citation/16528005/Effect_of_ezetimibe_on_the_in_vivo_kinetics_of_apoB_48_and_apoB_100_in_men_with_primary_hypercholesterolemia_ L2 - https://www.ahajournals.org/doi/10.1161/01.ATV.0000216750.09611.ec?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -